Dr. Bowdish is President & CEO at PIC Therapeutics. She brings more than 20 years of biopharmaceutical business and scientific leadership to the company.

Kathy was most recently at Sanofi, where she held multiple strategic roles. She launched and led Sanofi Sunrise, a venture investment and partnering vehicle to accelerate early stage pioneering science for patients benefit, and was later named Vice President and Head of R&D Strategy.

Prior to her leadership roles at Sanofi, Kathy co-founded or led several early-stage life science companies focused on biological therapies.  Kathy’s positions include: President & CSO, Permeon Biologics; President & CEO, Anaphore; President, Alexion Antibody Technologies and Senior Vice President, Alexion Pharmaceuticals; and Founder, CEO & CSO, Prolifaron, prior to its acquisition by Alexion.

Kathy has served on the Boards of MyoKardia, Warp Drive Bio, Portal Instruments, Thermalin, Permeon Biologics, Anaphore and Prolifaron, and most recently as an Observer on the DiCE Molecules Board. Kathy received her Ph.D. in molecular genetics from Columbia University College of Physicians and Surgeons, and her B.Sc. degree in biology from the College of William and Mary.